Shimara Gunawardana-Zeigler

Shimara Gunawardana-Zeigler

Auto-generated profile, based on publicly available information

Shimara Gunawardana-Zeigler

Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
ATAdit Tal
Adit Tal
SGShimara Gunawardana-Zeigler
Shimara Gunawardana-Zeigler
DPDa Peng
Da Peng
YTYuqi Tan
Yuqi Tan
NPNatalia Muñoz Perez
Natalia Muñoz Perez
DLDavid Loeb
David Loeb
Osteosarcoma is the most common primary malignant bone tumor in childhood. Patients who present with metastatic disease at diagnosis or relapse have a very poor prognosis, and this has not changed over the past four decades. The Wnt signaling pathway plays a role in regulating osteogenesis and is implicated in osteosarcoma pathogenesis. DKK-1 inhibits the canonical Wnt signaling pathway, causing inhibition of osteoblast differentiation and disordered bone repair. Our lab previously demonstrated that an mAb against DKK-1 prevented metastatic disease in a mouse model. This study expands upon those findings by demonstrating similar results with a small-molecule inhibitor of DKK-1, WAY262611, both in vitro and in vivo. WAY262611 was evaluated in vitro on osteosarcoma cell lines, including proliferation, caspase activation, cell-cycle analysis, and signaling pathway activation. We utilized our orthotopic implantation/amputation model of osteosarcoma metastasis in vivo to determine the impact of WAY262611 on primary tumor progression and metastatic outgrowth of disseminated tumor cells. Differentiation status was determined using single-cell RNA sequencing. We show here that WAY262611 activates canonical Wnt signaling, enhances nuclear localization and transcriptional activity of β-catenin, and slows proliferation of osteosarcoma cell lines. We also show that WAY262611 induces osteoblastic differentiation of a patient-derived xenograft of osteosarcoma in vivo, as well as inhibiting metastasis. This work credentials DKK-1 as a therapeutic target in osteosarcoma, allowing for manipulation of the Wnt signaling pathway and providing preclinical justification for the development of new biologics for the prevention of osteosarcoma metastasis.

2 May 2025
Verified
Other
Open access
ATAdit Tal
Adit Tal
SGShimara Gunawardana-Zeigler
Shimara Gunawardana-Zeigler
DPDa Peng
Da Peng
YTYuqi Tan
Yuqi Tan
NPNatalia Muñoz Perez
Natalia Muñoz Perez
DLDavid Loeb
David Loeb
Supplementary Table S1: Top 10 GO Biological Processes Enriched in Treated vs Control

17 June 2026
Verified
Other
Open access
ATAdit Tal
Adit Tal
SGShimara Gunawardana-Zeigler
Shimara Gunawardana-Zeigler
DPDa Peng
Da Peng
YTYuqi Tan
Yuqi Tan
NPNatalia Muñoz Perez
Natalia Muñoz Perez
DLDavid Loeb
David Loeb
Supplementary Table S1: Top 10 GO Biological Processes Enriched in Treated vs Control

17 June 2026
Verified
Other
Open access
ATAdit Tal
Adit Tal
SGShimara Gunawardana-Zeigler
Shimara Gunawardana-Zeigler
DPDa Peng
Da Peng
YTYuqi Tan
Yuqi Tan
NPNatalia Muñoz Perez
Natalia Muñoz Perez
DLDavid Loeb
David Loeb
Osteosarcoma is the most common primary malignant bone tumor in childhood. Patients who present with metastatic disease at diagnosis or relapse have a very poor prognosis, and this has not changed over the past four decades. The Wnt signaling pathway plays a role in regulating osteogenesis and is implicated in osteosarcoma pathogenesis. DKK-1 inhibits the canonical Wnt signaling pathway, causing inhibition of osteoblast differentiation and disordered bone repair. Our lab previously demonstrated that an mAb against DKK-1 prevented metastatic disease in a mouse model. This study expands upon those findings by demonstrating similar results with a small-molecule inhibitor of DKK-1, WAY262611, both in vitro and in vivo. WAY262611 was evaluated in vitro on osteosarcoma cell lines, including proliferation, caspase activation, cell-cycle analysis, and signaling pathway activation. We utilized our orthotopic implantation/amputation model of osteosarcoma metastasis in vivo to determine the impact of WAY262611 on primary tumor progression and metastatic outgrowth of disseminated tumor cells. Differentiation status was determined using single-cell RNA sequencing. We show here that WAY262611 activates canonical Wnt signaling, enhances nuclear localization and transcriptional activity of β-catenin, and slows proliferation of osteosarcoma cell lines. We also show that WAY262611 induces osteoblastic differentiation of a patient-derived xenograft of osteosarcoma in vivo, as well as inhibiting metastasis. This work credentials DKK-1 as a therapeutic target in osteosarcoma, allowing for manipulation of the Wnt signaling pathway and providing preclinical justification for the development of new biologics for the prevention of osteosarcoma metastasis.

2 May 2025
Verified
Other
Open access
ATAdit Tal
Adit Tal
SGShimara Gunawardana-Zeigler
Shimara Gunawardana-Zeigler
DPDa Peng
Da Peng
YTYuqi Tan
Yuqi Tan
NPNatalia Muñoz Perez
Natalia Muñoz Perez
DLDavid Loeb
David Loeb
Supplementary Figure S1 shows results from toxicity evaluation of WAY262611, the effect of WAY262611 on the growth of the primary tumor and on mouse survival, as well as examples of metastatic lesions.

17 June 2026
Verified
Other
Open access
ATAdit Tal
Adit Tal
SGShimara Gunawardana-Zeigler
Shimara Gunawardana-Zeigler
DPDa Peng
Da Peng
YTYuqi Tan
Yuqi Tan
NPNatalia Muñoz Perez
Natalia Muñoz Perez
DLDavid Loeb
David Loeb
Supplementary Figure S1 shows results from toxicity evaluation of WAY262611, the effect of WAY262611 on the growth of the primary tumor and on mouse survival, as well as examples of metastatic lesions.